This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Carcinoma in situ of skin피부의 제자리암 (피부제자리암)

📋 Contents and key points
A. Classification codesICD-10: D04 | D04.0 Carcinoma in situ of skin of lip | D04.1 Carcinoma in situ of eyelid | D04.2 Carcinoma in situ of ear and external auricular canal | D04.3 Carcinoma in situ of face | D04.4 Carcinoma in situ of scalp and neck | D04.5 Carcinoma in situ of trunk | D04.6 Carcinoma in situ of upper limb and shoulder | D04.7 Carcinoma in situ of lower limb and hip | D04.8 Carcinoma in situ of other skin | Special Copayment Reduction V193 (5% copayment, for 5 years from the registration date)
B. SynonymsBowen's disease, bowenoid papulosis, actinic keratosis (AK, solar keratosis), squamous cell carcinoma in situ of the skin (SCCIS), erythroplasia of Queyrat (Bowen's disease of the glans penis), arsenical keratosis, radiation keratosis
C. Adult onsetVery high — Bowen's disease mainly in older people in their 60s–70s; actinic keratosis in adults aged 40 and over with heavy smoking and sun exposure; extremely rare in children (except xeroderma pigmentosum)
Contents 1. History · 2. Causes · 3. Genetics · 4. Epidemiology · 5. Pathophysiology · 6. Symptoms · 7. Signs · 8. Screening · 9. Diagnosis · 10. Treatment · 11. Prognosis · 12. Prevention · 13. References
1. History summaryJohn Bowen (1912) gave the first systematic description of cutaneous CIS; concept of actinic keratosis as a precursor lesion of invasive SCC established; Mohs surgery developed in the 1930s.
2. Causes summaryCumulative UV exposure; arsenic; HPV (genital and periungual lesions); immunosuppression; radiation; history of PUVA therapy.
3. Genetics summaryTP53 and RAS mutations (UV signature, C→T); PTCH1 (basal cell carcinoma precursor); familial CDKN2A; arsenic-related TP53 abnormalities.
4. Epidemiology summaryActinic keratosis prevalence about 11–25% in adults aged 50 and over; Bowen's disease about 14–142 per 100,000 population; highest incidence in Australia and New Zealand.
5. Pathophysiology summaryUV → TP53 mutation in epidermal keratinocytes → clonal expansion → full-thickness atypia (CIS); field cancerization puts all photodamaged skin at risk.
6. Symptoms summaryActinic keratosis: rough, scaly erythematous plaques; Bowen's disease: slowly enlarging red scaly plaques, some itching; mostly painless.
7. Signs summaryStrawberry pattern (surface vessels) on dermoscopy; on tissue biopsy, atypical keratinocytes throughout the full thickness of the epithelium with the basement membrane intact.
8. Screening summaryRegular total-body skin examination for high-risk groups with photodamage; surveillance every 6–12 months for immunosuppressed patients; adjunctive use of dermoscopy.
9. Diagnosis summaryHistopathology of punch or excisional biopsy; p16 and Ki-67 IHC; dermoscopy; HPV typing (genital lesions).
10. Treatment summaryCryotherapy, curettage, electrocautery (AK); 5-FU and imiquimod cream; photodynamic therapy (PDT); Mohs surgery (high-risk sites); radiation (older patients).
11. Prognosis summaryRate of progression to invasive SCC after complete treatment of Bowen's disease 3–5%; actinic keratosis progresses to invasive disease at 1–16% per lesion per year; regular follow-up after treatment essential.
12. Prevention summaryUV protection (SPF 50+); smoking cessation; blocking arsenic exposure; regular skin examination for immunosuppressed patients; nicotinamide intake (high-risk groups).

1. History

The most important milestone in the history of carcinoma in situ of the skin (D04) is the two cases published in 1912 by the American dermatologist John T. Bowen in the Journal of Cutaneous and Genitourinary Diseases. Bowen described chronic erythematous plaque lesions that histologically showed proliferation of atypical cells throughout the full thickness of the epidermis with an intact basement membrane, and named them "precancerous dermatosis". This was the first description of what is now Bowen's disease (cutaneous squamous cell carcinoma in situ).

The concept of actinic keratosis (AK) had been known since the late 19th century, but in 1958 Helwig and Graham systematically demonstrated AK as a true precursor lesion of invasive squamous cell carcinoma (SCC), and the concept of progression from AK to SCC subsequently became established textbook knowledge. In the 1930s, Frederic E. Mohs developed the prototype of Mohs fixed-tissue surgery using a caustic zinc chloride paste, which later evolved into modern Mohs micrographic surgery using frozen sections and became the standard treatment for skin cancer and CIS in critical areas such as the face. The association of arsenic with skin cancer and CIS has been observed since the late 1800s, and even after organic arsenical preparations were discontinued in 1968, multiple Bowen's disease accompanied by visceral cancers (arsenic syndrome) has been reported in patients with a history of arsenic exposure.

Erythroplasia of Queyrat was described in 1911 by the French dermatologist Queyrat as red velvety lesions of the glans and inner prepuce, and was later recognized as a variant of Bowen's disease on the glans. The association between HPV and carcinoma in situ of the skin was studied in the 1970s–80s, and it was confirmed that HPV type 16 is frequently found especially in genital and periungual Bowen's disease.

2. Causes

Cumulative ultraviolet (UV) exposure is the most common cause of carcinoma in situ of the skin. Decades of accumulated sun exposure damage the DNA of skin keratinocytes (epidermal cells), which is why actinic keratosis and Bowen's disease occur mainly on sun-exposed areas such as the face, scalp, backs of the hands and forearms. UVB (280-315nm) in particular causes direct DNA damage (cyclobutane pyrimidine dimers).

Arsenic: chronic arsenic exposure (contaminated drinking water, past use of arsenic-containing pesticides, occupational exposure) increases the risk of multiple Bowen's disease, palmoplantar keratoses and visceral cancers (lung, bladder and kidney cancer). HPV infection: HPV types 16 and 18 are found in 50–80% of genital (glans, vulva, perianal) and periungual Bowen's disease. The HPV E6 and E7 proteins functionally suppress TP53 and RB1. Immunosuppression: in patients taking immunosuppressants (cyclosporine, azathioprine) after organ transplantation, the risk of cutaneous CIS and SCC increases 65–250-fold. PUVA therapy: long-term cumulative doses of photochemotherapy (psoralen + UVA) for psoriasis raise the risk of SCC and precursor lesions. Ionizing radiation: radiation keratosis and SCC may develop at radiation therapy sites years to decades later.

3. Genetics

TP53 mutation is the most frequent somatic mutation in cutaneous CIS, found in about 60–80% of Bowen's disease and 50–70% of actinic keratosis. It is characterized by UV-specific C→T (or CC→TT) transitions, the molecular fingerprint of direct UV damage (UV signature). Clonal expansion of epidermal keratinocyte clones bearing TP53 mutations, which gain a survival advantage against UV, is the key mechanism of actinic keratosis development.

RAS mutations (HRAS, KRAS) are found in some Bowen's disease and SCC. CDKN2A (p16) deletion or methylation is common in advanced lesions, abolishing the G1/S cell-cycle checkpoint. Familial skin cancer syndromes: CDKN2A germline mutations (familial atypical multiple mole melanoma syndrome), PTCH1 mutations (basal cell nevus syndrome, Gorlin syndrome, precursor of multiple basal cell carcinomas), and abnormalities of DNA repair genes such as FANCL (Fanconi anemia) raise the risk of cutaneous CIS. Xeroderma pigmentosum: defective nucleotide excision repair (NER) makes repair of UV damage impossible → multiple cutaneous CIS and invasive cancers from an early age. Specific TP53 hotspot mutations (an arsenic-UV co-induced pattern) have been reported in arsenic-related cutaneous CIS.

4. General epidemiology

Actinic keratosis (AK) is the most common precancerous skin lesion worldwide. In Australia AK is found in about 40–50% of adults aged 40 and over, in 10–20% of European adults, and more than 58 million people in the United States are estimated to have AK. In Korea, the prevalence of AK is lower than in Western countries because of the relatively darker skin of the population, but it is increasing with population aging and more outdoor activity.

The incidence of Bowen's disease (cutaneous squamous cell CIS) varies by country; a study in Scotland, UK, reported an annual incidence of 142 per 100,000 population. It occurs mainly in older people in their 60s–70s and is slightly more common in women. In Korea it is a relatively commonly diagnosed lesion in dermatology practice, but accurate epidemiological data are limited. Erythroplasia of Queyrat of the glans is more common in uncircumcised men. In immunosuppressed patients (after kidney transplantation), the incidence of cutaneous CIS reaches 10–60 times that of the general population.

5. Pathophysiology

Cutaneous CIS develops through the accumulation of multistep genetic changes in epidermal keratinocytes caused by carcinogenic stimuli such as UV. UV-induced TP53 mutation is the first decisive event. Keratinocytes with TP53 mutations resist UV-induced apoptosis signals, survive and undergo clonal expansion. TP53-mutant keratinocyte clones exist even in normal skin with aging, and the concept of field cancerization applies to all photodamaged skin.

Next, CDKN2A loss removes the G1/S checkpoint, and activation of the RAS/MAPK pathway promotes proliferation. Actinic keratosis (AK) is the stage at which atypical cells are present in only part of the thickness of the epidermis; when these atypical cells extend through the full thickness of the epidermis, it becomes carcinoma in situ (Bowen's disease, SCCIS). The basement membrane remains intact up to this stage, and when basement membrane invasion occurs, it becomes invasive SCC. HPV-related cutaneous CIS arises through a pathway in which the HPV E6 protein promotes ubiquitin-proteasome degradation of TP53 and E7 inactivates pRb, paralyzing cell-cycle control.

6. Symptoms

Actinic keratosis (AK): rough, scaly red or brown plaque lesions occurring on heavily sun-exposed areas (face, front of the scalp, ears, backs of the hands, forearms, etc.). A sandpaper-like rough feel when the skin is rubbed with a finger is characteristic. Some patients have mild itching or burning, but most are asymptomatic. Size ranges from a few mm to a few cm, and borders are often indistinct.

Bowen's disease (cutaneous CIS): it can occur anywhere on the skin but is common on sun-exposed areas, the genitals and the perianal area. The typical lesion is a slowly enlarging, well-demarcated red to reddish-brown plaque with scale or crust (scab) on the surface. It may reach several cm in size. Itching may be the main symptom, but painless asymptomatic lesions are also common. Erythroplasia of Queyrat of the glans appears as a red velvety plaque on the inner glans and may be accompanied by exudate or bleeding. If it progresses to invasive SCC, the lesion thickens or nodules and ulcers develop.

7. Signs

Dermoscopic findings: in Bowen's disease, a 'strawberry pattern' is characteristic — dotted and linear vessels surrounded by white scale. Glomerular vessels are specifically observed in Bowen's disease. Actinic keratosis on dermoscopy shows red perifollicular rims on a background of white scale, a strawberry pattern. Histopathological findings: cytological and architectural atypia throughout the full thickness of the epidermis, loss of polarity, pleomorphic nuclei, atypical mitoses, dyskeratotic cells. An intact basement membrane is the decisive finding of CIS. Immunohistochemistry: markedly increased Ki-67 proliferation index, p16 overexpression (HPV-related). Histological differential diagnosis: differentiation from superficial basal cell carcinoma, seborrheic keratosis, eczema and psoriasis is needed, and the diagnosis is confirmed by tissue biopsy.

8. Screening

National population screening for carcinoma in situ of the skin is not performed in most countries, including Korea. However, regular skin examination is recommended in the following high-risk groups. High-risk groups for photodamage: a total-body skin examination by a dermatologist once or twice a year is recommended for long-term outdoor workers, those in agriculture and fisheries, and adults aged 60 and over with decades of strong sun exposure.

Immunosuppressed patients: because the risk of cutaneous CIS and SCC is very high in patients taking immunosuppressants after organ transplantation such as kidney or heart, skin examination is performed at least every 6 months. Supplementation with nicotinamide (vitamin B3) (500mg twice daily) for skin cancer prevention has been shown to significantly reduce the incidence of new cutaneous CIS in high-risk groups (Chen et al., 2015). Xeroderma pigmentosum: because skin damage accumulates immediately on UV exposure, intensified UV protection from an early age and skin examination every 3–6 months are essential. People with a history of arsenic exposure: as a group at risk of multiple Bowen's disease, they need regular skin examination and surveillance for visceral cancers (lung cancer, bladder cancer).

9. Diagnosis

Confirmation of cutaneous CIS requires histopathological confirmation by tissue biopsy. For small lesions, complete excisional biopsy accomplishes diagnosis and treatment simultaneously. For large lesions, a punch biopsy (4-6mm) is taken from a representative area.

Histopathological criteria: cytological and architectural atypia throughout the full thickness of the epidermis (polar disorientation, nuclear pleomorphism, increased mitoses), basement membrane intact. Differentiation from actinic keratosis: in AK atypical cells are confined to part of the epidermis (basal layer to lower spinous layer), whereas in CIS atypia is full-thickness up to just below the stratum corneum. Immunohistochemistry: p16 (block-type overexpression in HPV-related CIS), p53 (aberrant expression in TP53-mutant types), Ki-67 (proliferative activity), BerEP4 (differentiation of squamous from basal cells). HPV typing: in genital or periungual Bowen's disease, HPV type is identified by PCR or ISH (helpful for treatment planning and testing of sexual partners). Dermoscopy: used to assess lesion characteristics and select biopsy sites.

10. Treatment

Treatment of cutaneous CIS is chosen according to the lesion's location and size and the patient's general and immune status.

Treatment of actinic keratosis (AK): cryotherapy (liquid nitrogen) is the most widely used first-line treatment for single or few lesions. 5-fluorouracil (5-FU) cream (0.5-5%): topical chemotherapy for extensive AK; applied for 2–4 weeks. Imiquimod 5% cream: treats AK and Bowen's disease through immune response modulation. 3% or 0.015% ingenol mebutate gel: short-term (2–3 days) topical treatment. Photodynamic therapy (PDT): light irradiation after application of ALA (5-aminolevulinic acid) or MAL (methyl aminolevulinate); cosmetically excellent results. Treatment of Bowen's disease (cutaneous CIS): standard surgical excision (3-5mm safety margin). Mohs surgery: sites where tissue preservation is important, such as the face, fingertips, ears and perianal area, or recurrent lesions. Cryotherapy, PDT, 5-FU, imiquimod: sites difficult to excise or multiple lesions. Radiation therapy: older patients and patients unfit for surgery.

11. Prognosis

With appropriate treatment, carcinoma in situ of the skin has a very good prognosis. Bowen's disease (cutaneous CIS): the rate of progression to invasive SCC after complete treatment is about 3–5%. If left untreated, about 3–5% of lesions progress to invasive SCC over 10–30 years. The recurrence rate after treatment varies by treatment method and is lowest after surgical excision (2–8%). The recurrence rate after Mohs surgery is the lowest, at less than about 2%.

Actinic keratosis (AK): the spontaneous regression rate is high, at about 20–30% per year, but some progress to invasive SCC. The annual SCC progression rate of an individual AK lesion is about 0.025–0.097%, but some studies show that the 10-year cumulative SCC risk exceeds 10% in patients with multiple lesions. Even after treatment, new lesions may continue to develop at the treated site and adjacent photodamaged skin because of field cancerization, so regular follow-up is needed. In immunosuppressed patients, the risk of Bowen's disease progressing to invasive SCC is much higher than in the general population.

12. Prevention

UV protection: apply SPF 50+ PA+++ sunscreen to all sun-exposed areas daily and reapply every 2–3 hours. Wear UV-protective clothing (UPF 50+), a wide-brimmed hat and UV-blocking sunglasses. Minimize outdoor activity from 10 a.m. to 4 p.m. Smoking cessation: smoking raises SCC risk and impairs skin circulation and immune function. Blocking arsenic exposure: use of safe water sources in areas using arsenic-contaminated groundwater. Protective equipment for workers with occupational arsenic exposure. Nicotinamide (vitamin B3) 500mg twice daily: shown in a randomized controlled trial to reduce new AK and cutaneous CIS by about 23% in high-risk groups such as immunosuppressed patients. HPV vaccine: may help prevent genital HPV-related cutaneous CIS. Immunosuppressed patients: where possible, minimize immunosuppressant doses; there are reports that switching to an mTOR inhibitor (everolimus) helps reduce skin cancer risk.


13. References

  1. Bowen JT. Precancerous dermatoses: a study of two cases of chronic atypical epithelial proliferation. J Cutan Dis. 1912;30:241-255.
  2. Goon PKC, Greenberg DC, Igali L, et al. Bowen's disease in the south east of England 1975-2005: Incidence, trends and risk factors. J Eur Acad Dermatol Venereol. 2011;25(2):171-176.
  3. Chen AC, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med. 2015;373(17):1618-1626.
  4. Moncrieff M, et al. Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52(6):1007-1011.
  5. Morton CA, et al. British Association of Dermatologists guidelines for the management of squamous cell carcinoma in situ (Bowen's disease) 2014. Br J Dermatol. 2014;170(2):245-260.
  6. Röwert-Huber J, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156 Suppl 3:8-12.
  7. NCCN Clinical Practice Guidelines in Oncology. Squamous Cell Skin Cancer. Version 2.2024. National Comprehensive Cancer Network, 2024.
  8. Neuber K, et al. S3 guideline actinic keratosis and cutaneous squamous cell carcinoma – update 2023. J Dtsch Dermatol Ges. 2023;21(10):1178-1197.
  9. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors. J Am Acad Dermatol. 2018;78(2):249-261.
  10. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol. 2000;42(1 Pt 2):11-17.